Pure Lithium’s Brine to Battery™ Technology Wins 2025 Green Chemistry Challenge Award
25.8.2025 11:00:00 CEST | Business Wire | Press Release
Pure Lithium, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that it has been awarded the 2025 Green Chemistry Challenge Award in the Chemical and Process Design for Circularity category for its Brine to Battery™ technology.
"We are honored to be acknowledged by the American Chemical Society, the nation’s premier organization of chemistry professionals, for our technology which reduces energy consumption and carbon emissions across the battery supply chain,” Pure Lithium Founder and Chief Executive Officer Emilie Bodoin said. “We have demonstrated that our technology is capable of eliminating some of the most energy intensive steps in anode manufacturing.”
Pure Lithium’s vertically integrated Brine to Battery™ technology seamlessly integrates lithium metal extraction and battery anode production, significantly reducing energy consumption and environmental impact associated with shipping materials across several continents. The company’s lithium metal batteries eliminate graphite, which is a main component of a lithium-ion battery. Instead, Pure Lithium extracts lithium metal from lithium brine which is abundant in North America to create a lithium metal anode that completely replaces today's graphite anode.
Pure Lithium’s lithium metal batteries are a step change in energy storage, with double the energy density of today's lithium-ion batteries, and the company has achieved unprecedented cycle life in small pouch cells, upwards of 5,000 cycles. Now the company is shifting from pure research and development to the prototyping phase at its new facilities in Chicago.
“The Green Chemistry Challenge Awards highlight how innovation in chemistry is driving solutions for a healthier, more sustainable world,” said American Chemical Society CEO Albert G. Horvath. “Congratulations to this year’s winners, whose work reflects the creativity and commitment of both academia and industry. Their achievements show how green chemistry continues to push the boundaries of science while making a lasting impact on society and the environment.”
This award follows several other recent successes for Pure Lithium and its technology. Pure Lithium won the R&D Achievement Award and Emilie Bodoin was recognized as an Innovator in Energy at the 2025 Reuters Global Energy Transition Awards. Emilie Bodoin was also recognized as the Trailblazing Woman of the Year at the Fastmarkets Voltas Awards.
Established by the U.S. Environmental Protection Agency in 1996, the Green Chemistry Challenge Awards recognize chemical technologies that incorporate the principles of green chemistry into chemical design, manufacture, and use. Winning technologies have been responsible for reducing the use or generation of nearly one billion pounds of hazardous chemicals, saving over 20 billion gallons of water, and eliminating nearly eight billion pounds of carbon dioxide equivalents released to the air.
About Pure Lithium
Pure Lithium is a disruptive lithium metal battery technology company led by inventor and lithium expert, CEO Emilie Bodoin. The Company's novel Brine to Battery™ technology combines metal extraction and anode production, unlocking unconventional sources of lithium. The resulting pure lithium metal anode is the core component of our lithium metal battery, a step change improvement over today’s lithium-ion technology in cell performance, cost, and safety. The battery is free of graphite, cobalt, nickel, and manganese. For more information, visit www.purelithium.io or email news@purelithium.io.
About The Green Chemistry Challenge Awards
The Green Chemistry Challenge Awards promote the environmental and economic benefits of developing and using novel green chemistry.
Since the inception of the awards 30 years ago, the American Chemical Society, one of the world's largest scientific societies, and the U.S. Environmental Protection Agency (EPA) have worked together to establish and promote the Green Chemistry Challenge Awards and have presented awards to 144 technologies that decrease hazardous chemicals and resources, reduce costs and protect public health. Building on this strong foundation, the American Chemical Society continues to support and celebrate outstanding achievements in green chemistry through these prestigious awards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250825476246/en/
Contacts
Ross Larsen, Head of Editorial, 33 Communications
purelithium@thirtythreecomms.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom